Charlotte Pawlyn, MD
Institute of Cancer Research
Sutton, United Kingdom
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover
Visit our website at: http://www.myeloma.org
Advertisement